Literature DB >> 26137280

Prognostic significance of osteopontin expression in non-small-cell lung cancer: A meta-analysis.

Xue-Lin Zou1, Chun Wang2, K E Liu3, Wen Nie4, Zhen-Yu Ding1.   

Abstract

Osteopontin (OPN) plays an important role in the progression and metastasis of cancer. However, the role of OPN as a prognostic factor in non-small-cell lung cancer (NSCLC) remains controversial. The aim of this study was to investigate the association between OPN expression and prognosis in patients with NSCLC using a meta-analysis. Based on PubMed, Ovid Medline, Embase, ISI, ScienceDirect and SpringerLink databases, related articles published prior to January, 2013 were collected. A meta-analysis was conducted to investigate the association of OPN expression with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC. Hazard ratio (HR) with 95% confidence interval (CI) was used to assess the strength of this association. A total of 6 studies, including 776 patients, were found to be eligible for the meta-analysis. No heterogeneity was observed in OS or PFS, whereas low OPN expression was found to be correlated with better OS (HR=0.57, 95% CI: 0.46-0.70) and PFS (HR=0.62, 95% CI: 0.49-0.77). This meta-analysis demonstrated an association of OPN with poor prognosis in NSCLC patients. However, prospective studies are required to confirm these findings.

Entities:  

Keywords:  meta-analysis; non-small-cell lung cancer; osteopontin; prognosis

Year:  2015        PMID: 26137280      PMCID: PMC4471529          DOI: 10.3892/mco.2015.517

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  31 in total

1.  A comparison of methods to detect publication bias in meta-analysis.

Authors:  P Macaskill; S D Walter; L Irwig
Journal:  Stat Med       Date:  2001-02-28       Impact factor: 2.373

Review 2.  Uncertainty in heterogeneity estimates in meta-analyses.

Authors:  John P A Ioannidis; Nikolaos A Patsopoulos; Evangelos Evangelou
Journal:  BMJ       Date:  2007-11-03

3.  Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma.

Authors:  N Shijubo; T Uede; S Kon; M Maeda; T Segawa; A Imada; M Hirasawa; S Abe
Journal:  Am J Respir Crit Care Med       Date:  1999-10       Impact factor: 21.405

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 5.  Osteopontin: role in cell signaling and cancer progression.

Authors:  Hema Rangaswami; Anuradha Bulbule; Gopal C Kundu
Journal:  Trends Cell Biol       Date:  2006-01-10       Impact factor: 20.808

Review 6.  Tumor angiogenesis of non-small cell lung cancer.

Authors:  Noriharu Shijubo; Hiroshi Kojima; Manabu Nagata; Takashi Ohchi; Akihiro Suzuki; Shosaku Abe; Noriyuki Sato
Journal:  Microsc Res Tech       Date:  2003-02-01       Impact factor: 2.769

Review 7.  The role of osteopontin in lung disease.

Authors:  Anthony O'Regan
Journal:  Cytokine Growth Factor Rev       Date:  2003-12       Impact factor: 7.638

8.  Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: a large cohort retrospective study.

Authors:  Li Zhang; Xue Hou; Shun Lu; Huilan Rao; Jinghui Hou; Rongzhen Luo; He Huang; Hongyun Zhao; Hong Jian; Zhiwei Chen; Meilin Liao; Xin Wang
Journal:  Lung Cancer       Date:  2010-01       Impact factor: 5.705

Review 9.  Osteopontin: a protein with diverse functions.

Authors:  D T Denhardt; X Guo
Journal:  FASEB J       Date:  1993-12       Impact factor: 5.191

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  6 in total

1.  Macrophages Cytokine Spp1 Increases Growth of Prostate Intraepithelial Neoplasia to Promote Prostate Tumor Progression.

Authors:  Justin K Messex; Crystal J Byrd; Mikalah U Thomas; Geou-Yarh Liou
Journal:  Int J Mol Sci       Date:  2022-04-12       Impact factor: 6.208

2.  Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation.

Authors:  Yu-Jin Wang; Qing-Wen Wang; Dong-Hu Yu; Cong-Kuan Song; Zi-Xin Guo; Xiao-Ping Liu; Chen Chen; Jie Yao; Ai-Fen Wang; Wei-Dong Hu
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-13       Impact factor: 4.553

3.  Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.

Authors:  Yulong Fu; Yang Zhang; Zhe Lei; Ting Liu; Tingting Cai; Anqi Wang; Wenwen Du; Yuanyuan Zeng; Jianjie Zhu; Zeyi Liu; Jian-An Huang
Journal:  J Hematol Oncol       Date:  2020-12-07       Impact factor: 17.388

4.  Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

Authors:  Vasiliki Petta; Stelios Loukides; Konstantinos Kostikas; Andriana I Papaioannou; Georgios Papatheodorou; Kyriaki Cholidou; Ioannis Tomos; Spyridon Papiris; Nikolaos G Koulouris; Petros Bakakos
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

5.  Roles of osteopontin and matrix metalloproteinase-7 in occurrence, progression, and prognosis of nonsmall cell lung cancer.

Authors:  Ying Sun; Dan Li; Xiao-Hong Lv; Shu-Cheng Hua; Ji-Chang Han; Feng Xu; Xian-Dong Li
Journal:  J Res Med Sci       Date:  2015-12       Impact factor: 1.852

6.  Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis.

Authors:  Xiaobin Gu; Xian-Shu Gao; Mingwei Ma; Shangbin Qin; Xin Qi; Xiaoying Li; Shaoqian Sun; Hao Yu; Wen Wang; Dong Zhou
Journal:  Oncotarget       Date:  2016-10-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.